🧱 Base Lab Panel

What this panel can settle, and by what logic

A broad panel bought with no complaint attached answers a different question from a targeted one. It is not asked to explain a symptom; it is asked which of the silent, common, early problems you already have. Three of them are genuinely settled here, and they are settled because the markers sit together.

1. HbA1c (Hemoglobin A1c) beside fasting glucose on the Comprehensive Metabolic Panel (CMP). HbA1c integrates roughly 8 to 12 weeks of glycemia while a fasting glucose is one morning, so the pair separates a bad breakfast from a trend Krhač 2019. An HbA1c of 5.9% with a fasting glucose of 94 mg/dL is early metabolic drift; the same 94 mg/dL with an HbA1c of 5.1% is a normal morning.
2. ALT on the Comprehensive Metabolic Panel (CMP), read as a trend rather than a flag. Alanine aminotransferase is the commonest abnormal number on any broad panel and it is usually metabolic rather than damage; cumulative high-normal ALT tracks incident steatotic liver disease in a rising linear relationship Lonardo 2024. An ALT of 38 U/L today and 22 U/L 2 years ago is information even though both are ‘in range’.
3. eGFR read against your own muscle mass. Creatinine is a muscle metabolite, so a heavily muscled man reads a falsely low eGFR and a sarcopenic one a falsely high result. Where creatinine-based and cystatin C-based estimates disagree, the discordance itself carries information about which estimate to believe Wang 2023. Cystatin C with eGFR is the marker that resolves it and it is not in this panel.

What it cannot settle, and what would

Normal liver enzymes do not exclude fatty liver, and this is the single most misread result on a broad panel. In a middle-aged population with overweight and normal liver enzymes, MASLD was present in 42% — 47% of the men and 36% of the women van Son 2024. Read the other way round, more than 80% of people with fatty liver have an ALT inside the reference interval Lonardo 2024. A clean Comprehensive Metabolic Panel (CMP) is not a clean liver; the test that answers it is imaging or a fibrosis score such as the Enhanced Liver Fibrosis (ELF) Test test.

It cannot give you a real cardiovascular risk number. A standard Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) reports LDL cholesterol, which is a concentration of cholesterol rather than a count of atherogenic particles. Among 13,015 statin-treated adults followed for a median of 8 years, apolipoprotein B and non-HDL cholesterol reflected residual risk better than LDL cholesterol did Johannesen 2021. ApoB (Apolipoprotein B) costs little and is not in this panel; Lipoprotein(a) — Lp(a) is measured once in a lifetime and is not here either.

It cannot settle a thyroid question, an iron question or a hormone question in the sense people expect. “Hormone status” in a bundle this size is a screen, not a workup: a single TSH (Thyroid-Stimulating Hormone) does not separate autoimmune thyroid disease from a stressed axis without Thyroid Antibodies (TPO + TgAb), and there is no Ferritin here at all.

And at this price it cannot beat the tier above it. A panel at $250 sits close enough to a $495 comprehensive that the real question is whether double the money buys 4 times the markers. For most people buying once a year, it does.

Draw conditions that decide whether the money is wasted

A broad panel is drawn badly more often than a targeted one, because nobody told the buyer it had conditions.

1. Fast 9 to 12 hours. Fasting glucose and triglycerides on the Comprehensive Metabolic Panel (CMP) and Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) are the two numbers that move most with a meal, and a non-fasted triglyceride of 220 mg/dL becomes an LDL calculation nobody should act on.
2. HbA1c (Hemoglobin A1c) needs no fast at all, which is the useful half of the pair: it is the marker to repeat opportunistically because it reflects 8 to 12 weeks of glycemia rather than this morning Krhač 2019.
3. No heavy training in the 48 hours before. Skeletal muscle releases creatine kinase and moves ALT, AST and creatinine together, and on a broad panel that produces the classic false alarm: three flagged results in one column after a leg session.
4. Not within 2 weeks of an illness, which shifts the white cell differential on the Complete Blood Count (CBC) with Differential and the acute-phase side of the chemistry at once.

How you would know it answered your question, and what each pattern means next

A broad panel with no complaint attached needs a reading order or it just produces anxiety about whichever number is flagged. Read it in this order and act only on these.

• HbA1c (Hemoglobin A1c) 5.7 to 6.4%: prediabetes. Add Fasting Insulin, which this panel does not carry and which is where the mechanism shows up years earlier Krhač 2019. Retest HbA1c at 12 weeks — not sooner, because it averages the life of a red cell.
• ALT above 30 U/L in a man or 20 U/L in a woman: assume metabolic liver disease until shown otherwise, and note that a normal value would not have excluded it van Son 2024. The next test is imaging or Enhanced Liver Fibrosis (ELF) Test, not a repeat Comprehensive Metabolic Panel (CMP).
• eGFR under 60 mL/min/1.73m² with a normal urinalysis: repeat with Cystatin C with eGFR before accepting it, especially if you carry a lot of muscle Wang 2023.
• LDL cholesterol in range: that is not the end of the cardiovascular question. ApoB (Apolipoprotein B) once, and Lipoprotein(a) — Lp(a) once in your life, settle more than a repeat lipid panel ever will Johannesen 2021.
• Everything normal: the next panel is worth buying in 12 months, not in 3. Almost nothing here moves meaningfully inside a quarter, and the pair of numbers that do — ALT and HbA1c — are the two worth trending Lonardo 2024.

Sources read for these sections

• Lonardo A. Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker!. World Journal of Gastroenterology 2024 · PMID 38983954
• van Son KC, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore) 2024 · PMID 38181294
• Wang Y, et al. Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR. Kidney Medicine 2023 · PMID 37753251
• Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World Journal of Diabetes 2019 · PMID 30697366
• Johannesen CDL, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology 2021 · PMID 33736827